Ruxolitinib Consistent in Safety, Tolerability Over 52-Weeks in Children with Extensive Atopic Dermatitis
Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.
United States Robert Bissonnette Innovaderm Research Innovaderm Research Robert Bissonnette Revolutionizing Atopic Dermatitis Maximum Use Trial
Source: hcplive.com